title: [A randomized controlled study on imipenem/cilastatin sodium in comparison to aztreonam + lincomycin in treating severe infections in patients with malignant tumors or hematological diseases].
abstract: A randomized controlled study was conducted to compare effects of imipenem (IPM) (1.0-1.5 g/day) with those of aztreonam (AZT) (4 g/day) +lincomycin (LCM) (1,200-2,400 mg/day) in patients with malignant tumors or hematological diseases and severe infections. A total of 95 patients entered the study between October 1989 and March 1991. Forty-seven patients were treated with IPM and the remaining 48 patients were given AZT+LCM. No statistically significant differences existed in age, sex or underlying diseases between the 2 groups. Overall, the clinical cure rate of the IPM group was 53%; This was significantly higher than the 31% cure rate obtained in the AZT+LCM group (P less than 0.05). The difference was significant in patients whose granulocyte counts were less than 1,000/microliters, but not in those whose granulocyte counts were 1,000/microliters or higher. Side effects were observed in 5 patients given IPM and one given AZT+LCM. In conclusion, no significant differences appeared to exist regarding clinical efficacy and safety between the 2 treatment regimens.
authors.affiliation: Aomori Prefectural Hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Sakata
authors.forename: Y
authors.initials: Y
authors.lastname: Sawada
authors.forename: K
authors.initials: K
authors.lastname: Kuroe
authors.forename: S
authors.initials: S
authors.lastname: Nakaji
authors.forename: H
authors.initials: H
authors.lastname: Takami
authors.forename: K
authors.initials: K
authors.lastname: Tsushima
authors.forename: S
authors.initials: S
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Ogasawara
authors.forename: H
authors.initials: H
authors.lastname: Shinagawa
authors.forename: N
authors.initials: N
authors.lastname: Soma
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001398:Aztreonam / Q000627:therapeutic use*; D015377:Cilastatin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D008034:Lincomycin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy*; D018805:Sepsis / Q000150:complications / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy*
chemical_list: D015377:Cilastatin; D015378:Imipenem; D008034:Lincomycin; D001398:Aztreonam